A Retrospective Multicenter Analysis of the Safety and Efficacy of Brentuximab Vedotin (BV) As Monotherapy or in Combination with Bendamustine (BV-B) in Relapsed Refractory Classic Hodgkin Lymphoma (cHL) in Argentina

Authors :: Negri Aranguren, Florencia
Cranco, Santiago
Shanley, Claudia
Fernandez, Isolda I.
Prates, Maria Virginia
Otero, Victoria
Fiad, Lorena
Foncuberta, Maria Cecilia
Miodosky, Marcela
Pavlovsky, Miguel A.
Kuminsky, Gustavo
Bordone, Javier
Wannesson, Bruno
Corso, Ariel Corso
Riveros, Dardo
Marquez, Marisa
Jarchum, Gustavo
Jarchum, Maria Sol
Cerutti, Ider Ramon
Bistmas, Alicia
Tamashiro, Monica
De Stefano, Giselda
Navieckas, Alicia
Cugliari, Silvana
Negri Aranguren, Pedro
Balaguer, Gabriela
Tosin, Maria
Remaggi, Guillermina
Altuve, Juan
Garcia, Juan Jose
Ferrari, Luciana C.
Klein, Graciela
Guanchiale, Luciana
Beligoy, Luis
Marull, Mariana
Dacunto, Maria Cecilia
Zerga, Marta Elisa
Kurgansky, Nicolas Matias
Pujol, Marcelo
Taus, Rossana L.
Sackman, Federico
Canosa, Veronica Cintia
Cruset, Soledad
Riddick, Maximiliano
Pavlovsky, Astrid
Source :: Blood; December 2017, Vol. 130 Issue: 1, Number 1 Supplement 1 p4089-4089, 1p
Publication Year :: 2017
Abstract: TITLE:A retrospective multicenter analysis of the safety and efficacy of Brentuximab Vedotin (BV) as monotherapy or in combination with Bendamustine (BV-B) in relapsed refractory Classic Hodgkin Lymphoma (cHL) in Argentina.

Full Text Access

Tools